Quick answer: Florida requires synchronous documented good faith examinations for initial compounded GLP-1 prescribing, moderate Corporate Practice of Medicine enforcement, and physician medical director oversight of clinical protocols. Autonomous practice ARNPs (per HB 607, effective 2020) have independent prescriptive authority for primary care including GLP-1, but compounded medications and complex protocols typically still require physician medical director oversight.
Florida is the third-largest compounded GLP-1 market with a uniquely aggressive Department of Health stance on telehealth-only weight-loss programs. The Florida Medical Board and Board of Pharmacy coordinate enforcement against non-compliant programs.
The five clinical and regulatory parameters that determine whether a compounded GLP-1 program is defensible under Florida board scrutiny.
Synchronous telehealth is required for initial prescribing. Florida's Telehealth Act (§456.47) requires a documented practitioner-patient relationship before prescribing any medication via telehealth.
No mandatory in-person follow-up for compounded GLP-1, but Florida expects documented clinical evaluation at appropriate intervals and adverse event reporting.
Florida Board of Pharmacy requires nonresident pharmacy permits for any pharmacy shipping prescriptions to Florida patients, including 503A compounding pharmacies. Florida has been particularly active in auditing compounding pharmacies serving telehealth weight-loss programs.
Autonomous practice ARNPs (per HB 607, effective 2020) have independent prescriptive authority for primary care including GLP-1, but compounded medications and complex protocols typically still require physician medical director oversight.
Compounded semaglutide is non-scheduled. Florida has specific PDMP (E-FORCSE) reporting requirements for Schedule II-V controlled substances that may pair with weight-loss protocols.
Specific Florida statute and regulatory citations operators should reference when structuring a compliant compounded GLP-1 program.
Establishes the standard of care for telehealth practice in Florida, including requirements for establishing a practitioner-patient relationship via telehealth before prescribing.
Florida Medical Practice Act provisions defining disciplinary grounds, including prescribing without an examination and inadequate medical records — frequently cited in enforcement against non-compliant telehealth weight-loss programs.
Florida pharmacy licensure statute, including the nonresident pharmacy permit requirement for out-of-state pharmacies shipping to Florida patients.
Establishes autonomous practice authority for qualifying ARNPs in Florida — relevant to NP-staffed GLP-1 programs operating without physician delegation.
Take the assessment — tell us your specialty + target states and we'll map your gaps and what onboarding looks like for you.
Authoritative Florida regulators with jurisdiction over telehealth compounded GLP-1 programs.
Physician licensure and CPOM-adjacent disciplinary action
Visit official sitePharmacy licensure, nonresident permits, and compounding oversight
Visit official siteARNP licensure including autonomous practice registration
Visit official siteRegulatory Information Disclaimer
The telehealth compliance information for Florida presented on this page is provided for general informational purposes only and should not be construed as legal advice. The telehealth regulatory landscape is evolving rapidly, with state legislatures, medical boards, and federal agencies frequently updating rules, guidance, and enforcement priorities. While TrueEval makes every effort to keep this information current and accurate, we cannot guarantee that all details reflect the very latest regulatory changes at the time of your visit.
We strongly recommend consulting with a qualified healthcare attorney or compliance professional before making business decisions based on this information. For the most current regulatory requirements, refer directly to your state medical board and relevant licensing authorities. Last reviewed: February 2026.
Take the assessment — tell us your specialty + target states and we'll map your gaps and what onboarding looks like for you.